PHK
BCRX icon

Point72 Hong Kong’s BioCryst Pharmaceuticals BCRX Stock Holding History

Point72 Hong Kong’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11,428
Closed -$68.5K – 550
2023
Q4 		$68.5K Buy
+11,428
New +$66.2K ﹤0.01% 507
2022
Q4 		– Sell
-18,428
Closed -$232K – 237
2022
Q3 		$232K Buy
+18,428
New +$237K 0.01% 1005
2022
Q2 		– Sell
-7,265
Closed -$118K – 1921
2022
Q1 		$118K Buy
+7,265
New +$117K ﹤0.01% 1107
2021
Q4 		– Sell
-1,981
Closed -$28K – 1893
2021
Q3 		$28K Buy
+1,981
New +$31.2K ﹤0.01% 1632
2021
Q2 		– Sell
-4,618
Closed -$47K – 1921
2021
Q1 		$47K Buy
4,618
+350
+8% +$3.61K ﹤0.01% 1295
2020
Q4 		$32K Buy
+4,268
New +$22K ﹤0.01% 1328
2020
Q3 		– Sell
-7,184
Closed -$34K – 1199
2020
Q2 		$34K Buy
7,184
+4,426
+160% +$17.7K ﹤0.01% 803
2020
Q1 		$6K Buy
2,758
+204
+8% +$562 ﹤0.01% 755
2019
Q4 		$9K Buy
+2,554
New +$6.42K ﹤0.01% 986
2019
Q2 		– Sell
-2,507
Closed -$20K – 1122
2019
Q1 		$20K Buy
2,507
+2,307
+1,154% +$19.8K 0.01% 675
2018
Q4 		$2K Buy
+200
New +$1.55K ﹤0.01% 722

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Point72 Hong Kong's BCRX Position: Q1 2024 in Review

Point72 Hong Kong sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2024, closing a stake of 11,428 shares — an estimated $68.5K sold.

Point72 Hong Kong first reported a position in BCRX in Q4 2018 and held it in 11 quarters. The position peaked at $232K in Q3 2022. 238 funds tracked by Wall St. Rank hold BCRX as of Q1 2024.

  • Point72 Hong Kong reported no remaining BioCryst Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Point72 Hong Kong sold 11,428 BioCryst Pharmaceuticals shares in Q1 2024, an estimated $68.5K.
  • Point72 Hong Kong first reported a position in BioCryst Pharmaceuticals in Q4 2018 and held it in 11 quarters.
  • Point72 Hong Kong's BioCryst Pharmaceuticals position peaked at $232K in Q3 2022.
  • 238 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2024.

Based on Point72 Hong Kong's 13F filing for Q1 2024, filed 15 May 2024.